53 related articles for article (PubMed ID: 15289309)
1. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy.
Lu Y; Bellgrau D; Dwyer-Nield LD; Malkinson AM; Duke RC; Rodell TC; Franzusoff A
Cancer Res; 2004 Aug; 64(15):5084-8. PubMed ID: 15289309
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
Chaft JE; Litvak A; Arcila ME; Patel P; D'Angelo SP; Krug LM; Rusch V; Mattson A; Coeshott C; Park B; Apelian DM; Kris MG; Azzoli CG
Clin Lung Cancer; 2014 Nov; 15(6):405-10. PubMed ID: 25044103
[TBL] [Abstract][Full Text] [Related]
3. Role of oncogenic KRAS in the prognosis, diagnosis and treatment of colorectal cancer.
Zhu G; Pei L; Xia H; Tang Q; Bi F
Mol Cancer; 2021 Nov; 20(1):143. PubMed ID: 34742312
[TBL] [Abstract][Full Text] [Related]
4. Lyophilized yeast powder for adjuvant free thermostable vaccine delivery.
Kumar R; Kharbikar BN
Appl Microbiol Biotechnol; 2021 Apr; 105(8):3131-3143. PubMed ID: 33834253
[TBL] [Abstract][Full Text] [Related]
5. A Phase 2 Randomized Placebo-Controlled Adjuvant Trial of GI-4000, a Recombinant Yeast Expressing Mutated RAS Proteins in Patients with Resected Pancreas Cancer.
Muscarella P; Bekaii-Saab T; McIntyre K; Rosemurgy A; Ross SB; Richards DA; Fisher WE; Flynn PJ; Mattson A; Coeshott C; Roder H; Roder J; Harrell FE; Cohn A; Rodell TC; Apelian D
J Pancreat Cancer; 2021; 7(1):8-19. PubMed ID: 33786412
[No Abstract] [Full Text] [Related]
6. Targeting KRAS in Colorectal Cancer.
Wang C; Fakih M
Curr Oncol Rep; 2021 Feb; 23(3):28. PubMed ID: 33582927
[TBL] [Abstract][Full Text] [Related]
7. Enhancing anticancer activity of checkpoint immunotherapy by targeting RAS.
Ward AB; Keeton AB; Chen X; Mattox TE; Coley AB; Maxuitenko YY; Buchsbaum DJ; Randall TD; Zhou G; Piazza GA
MedComm (2020); 2020 Sep; 1(2):121-128. PubMed ID: 33073260
[TBL] [Abstract][Full Text] [Related]
8. Whole Recombinant Saccharomyces cerevisiae Yeast Expressing Ras Mutations as Treatment for Patients With Solid Tumors Bearing Ras Mutations: Results From a Phase 1 Trial.
Cohn A; Morse MA; O'Neil B; Whiting S; Coeshott C; Ferraro J; Bellgrau D; Apelian D; Rodell TC
J Immunother; 2018 Apr; 41(3):141-150. PubMed ID: 29528991
[TBL] [Abstract][Full Text] [Related]
9. GI-19007, a Novel Saccharomyces cerevisiae-Based Therapeutic Vaccine against Tuberculosis.
King TH; Shanley CA; Guo Z; Bellgrau D; Rodell T; Furney S; Henao-Tamayo M; Orme IM
Clin Vaccine Immunol; 2017 Dec; 24(12):. PubMed ID: 29046306
[TBL] [Abstract][Full Text] [Related]
10. Kirsten Ras* oncogene: significance of its discovery in human cancer research.
Tsuchida N; Murugan AK; Grieco M
Oncotarget; 2016 Jul; 7(29):46717-46733. PubMed ID: 27102293
[TBL] [Abstract][Full Text] [Related]
11. Protection against Experimental Cryptococcosis following Vaccination with Glucan Particles Containing Cryptococcus Alkaline Extracts.
Specht CA; Lee CK; Huang H; Tipper DJ; Shen ZT; Lodge JK; Leszyk J; Ostroff GR; Levitz SM
mBio; 2015 Dec; 6(6):e01905-15. PubMed ID: 26695631
[TBL] [Abstract][Full Text] [Related]
12. Oral application of freeze-dried yeast particles expressing the PCV2b Cap protein on their surface induce protection to subsequent PCV2b challenge in vivo.
Patterson R; Eley T; Browne C; Martineau HM; Werling D
Vaccine; 2015 Nov; 33(46):6199-205. PubMed ID: 26476879
[TBL] [Abstract][Full Text] [Related]
13. Novel approaches in the management of pancreatic ductal adenocarcinoma: potential promises for the future.
Goel G; Sun W
J Hematol Oncol; 2015 May; 8():44. PubMed ID: 25935754
[TBL] [Abstract][Full Text] [Related]
14. Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR.
Richer AL; Friel JM; Carson VM; Inge LJ; Whitsett TG
Pharmgenomics Pers Med; 2015; 8():63-79. PubMed ID: 25897257
[TBL] [Abstract][Full Text] [Related]
15. Exploiting fungal cell wall components in vaccines.
Levitz SM; Huang H; Ostroff GR; Specht CA
Semin Immunopathol; 2015 Mar; 37(2):199-207. PubMed ID: 25404118
[TBL] [Abstract][Full Text] [Related]
16. Advanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.
Chiu JW; Wong H; Leung R; Pang R; Cheung TT; Fan ST; Poon R; Yau T
Oncologist; 2014 Sep; 19(9):937-50. PubMed ID: 25117068
[TBL] [Abstract][Full Text] [Related]
17. Whole Pichia pastoris yeast expressing measles virus nucleoprotein as a production and delivery system to multimerize Plasmodium antigens.
Jacob D; Ruffie C; Dubois M; Combredet C; Amino R; Formaglio P; Gorgette O; Pehau-Arnaudet G; Guery C; Puijalon O; Barale JC; Ménard R; Tangy F; Sala M
PLoS One; 2014; 9(1):e86658. PubMed ID: 24475165
[TBL] [Abstract][Full Text] [Related]
18. Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit.
Arnold M; Durairaj V; Mundt E; Schulze K; Breunig KD; Behrens SE
PLoS One; 2012; 7(9):e42870. PubMed ID: 23024743
[TBL] [Abstract][Full Text] [Related]
19. IL-6-inducing whole yeast-based immunotherapy directly controls IL-12-dependent CD8 T-cell responses.
Tamburini BA; Kedl RM; Bellgrau D
J Immunother; 2012 Jan; 35(1):14-22. PubMed ID: 22130158
[TBL] [Abstract][Full Text] [Related]
20. Potential targets for pancreatic cancer immunotherapeutics.
Dodson LF; Hawkins WG; Goedegebuure P
Immunotherapy; 2011 Apr; 3(4):517-37. PubMed ID: 21463193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
